BEST of ASCO Portugal 2024 - CR

Abstract

In the context of prostate cancer, we highlight a new pharmacological group that promises to revolutionize the future, and we discuss data that reinforce our current knowledge. In short: “something new” (ARV-766), “something old” (CHAARTED2) and “something borrowed” from ESMO 2023 (EMBARK). HERCULES, a penile cancer trial, was also one of the studies selected, largely due to the poor prognosis that characterizes this pathology, but also for the feat that it is, carrying out a prospective randomized study (Phase II) as part of a disease orphan.